Roch Houot

机构：Inserm, Université Rennes 2, Centre Hospitalier Universitaire de Rennes, Microenvironment and B-cells: Immunopathology, Cell, Differentiation and Cancer, Université de Rennes · ORCID：0000-0003-1729-8213

发表论文 493 篇 · 总被引 14622 次 · h-index 60

代表论文

• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 20)
• Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3 (2025 · Blood · 被引 8)
• Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry (2025 · Clinical Microbiology and Infection · 被引 8)
• Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry (2025 · Blood Advances · 被引 5)
• Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE (2025 · Blood · 被引 2)
• Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study (2026 · Blood Advances · 被引 1)